Vaccines for colorectal cancer

Herbert J. Zeh, Kevin Stavely-O'Carroll, Michael A. Choti

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations

Abstract

Despite recent advances in the treatment of colorectal cancer, the overall survival rate for those patients with advanced locoregional disease remains less than 50%. Although adjuvant systemic chemotherapy has improved survival of these patients, more effective therapies are needed. Immunotherapy is an approach that could have a particular role in the adjuvant therapy of colorectal cancer. There is now convincing evidence that the immune system can specifically recognize and destroy malignant cells. Although both antibody- and T-cell-mediated anti-tumor responses have been documented, the cellular immune response with its direct cytotoxic mechanisms is felt to be the principal anti-tumor arm of the immune system. Analysis of the T cells that recognize tumors has led to the identification and characterization of many tumor-associated antigens including several colorectal antigens. Current approaches to developing a vaccine for colorectal cancer use our expanded understanding of these tumor-associated antigens and the conditions that allow development of an effective cellular immune response to them.

Original languageEnglish (US)
Pages (from-to)307-313
Number of pages7
JournalTrends in Molecular Medicine
Volume7
Issue number7
DOIs
StatePublished - Jul 14 2001

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology

Fingerprint Dive into the research topics of 'Vaccines for colorectal cancer'. Together they form a unique fingerprint.

Cite this